Journal
WORLD JOURNAL OF CLINICAL CASES
Volume 7, Issue 14, Pages 1753-1763Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v7.i14.1753
Keywords
Uterine sarcoma; Uterine leiomyosarcoma; Endometrial stromal sarcoma; Adenosarcoma; Adjuvant therapy; Chemotherapy; Radiotherapy
Categories
Ask authors/readers for more resources
Uterine sarcomas (US) are rare mesenchymal tumours accounting approximately for 3%-7% of all uterine cancers. Histologically, US are classified into mesenchymal tumours or mixed epithelial and mesenchymal tumours. The group of mesenchymal tumours indudes uterine leiomyosarcoma (uLMS, 65% of cases), endometrial stromal sarcoma (ESS, 21%) - traditionally divided into low grade (LG-ESS) and high grade-undifferentiated uterine sarcoma (5%) and other rare subtypes such as alveolar or embryonal rhabdomyosarcoma. Despite the fact that several drugs demonstrated clinical activity in advanced or metastatic settings, the role of postoperative therapy in US remains controversial. In this review, we have summarised the current state of the art, including the chief trials on adjuvant treatment modalities in US, especially focusing on uLMS, LG-ESS and other rare histotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available